Business Context and Reporting Period
Sunshine Biopharma Inc., an emerging growth company incorporated in Colorado, filed this Form 8-K on April 13, 2020. The filing addresses the company's inability to meet the original March 30, 2020, deadline for its Annual Report on Form 10-K for the fiscal year ended December 31, 2019.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely as a notice of a filing delay and contains no financial data.
Material Changes
There are no material financial changes reported in this filing. The primary event is the operational disruption caused by the COVID-19 pandemic, which has forced the company's accounting staff in Montreal and Denver, as well as its directors, consultants, and auditors, into remote work and citywide lockdowns.
Guidance, Outlook, and Risks
- Regulatory Relief: The company is relying on an SEC Order dated March 4, 2020, to grant an exemption from specified provisions of the Exchange Act due to the pandemic.
- Revised Filing Date: Management expects to file the 2019 10-K no later than May 29, 2020, which represents a 60-day extension from the original deadline.
- Risks: The primary risk cited is the inability to complete the annual report in a timely manner due to lockdown restrictions affecting key personnel and auditors.
Investor Verification Checklist
- Verify the actual filing date of the 2019 Form 10-K to ensure it was submitted by the May 29, 2020, deadline.
- Review the delayed 2019 10-K for any material changes in financial position or going concern warnings once filed.
- Confirm the company's continued status as an emerging growth company and its compliance with related reporting exemptions.